This Biotech Stock Could Cure Your Portfolio's Pain

• Arcutis already has its cardinal cause approved for assorted diseases and concentrations.

• Sales are expanding rapidly, and Arcutis is positioned for growth.

• 10 stocks we similar amended than Arcutis Biotherapeutics ›

Investors seeking a biotech banal with important upside imaginable to adhd to their portfolio whitethorn privation to see Arcutis Biotherapeutics (NASDAQ: ARQT). The banal terms is already up 112% successful 2025, arsenic I write, but determination could beryllium much to travel successful the adjacent fewer years. Here's why.

The company's superior merchandise is Zoryve, a non-steroidal topical medicine disposable successful pick and foam formulations, which treats a assortment of inflammatory tegument diseases, including plaque psoriasis, atopic dermatitis (also known arsenic eczema), and seborrheic dermatitis. It contains the progressive constituent roflumilast, a PDE4 inhibitor that reduces the skin's inflammatory response.

Arcutis has already received support crossed a scope of applications and indications, with the adjacent support apt to beryllium for Zoryve pick successful children aged 2 to 5 years old. Arcutis besides has Zoryve successful signifier 2 trials for 3 different indications/concentrations.

Sales are increasing powerfully this year, with third-quarter nett merchandise gross of $99.2 million, up 122% compared to the aforesaid play past twelvemonth and 22% compared to the 2nd 4th of 2025. Wall Street expects $358 cardinal successful income for 2025 and past $467 cardinal successful 2026.

CEO Frank Watanabe believes highest roflumilast/Zoryve income could beryllium $2.6 cardinal to $3.5 billion, and considering the existent marketplace headdress is $3.6 billion. Wall Street analysts judge Arcutis could person nett income nett margins of 30%. The banal appears to beryllium a large worth if Watanabe is right, and Arcutis tin travel anyplace adjacent his highest income projection. Meanwhile, the institution has different drug, ARQ-23, which is aimed astatine reducing inflammatory immune responses and is successful early-stage development.

With a comparatively low-risk support process connected way and bully upside imaginable from maintaining its income momentum, Arcutis is an charismatic banal for growth-oriented investors.

Before you bargain banal successful Arcutis Biotherapeutics, see this:

The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Arcutis Biotherapeutics wasn’t 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.

Consider erstwhile Netflix made this database connected December 17, 2004... if you invested $1,000 astatine the clip of our recommendation, you’d person $513,353!* Or erstwhile Nvidia made this database connected April 15, 2005... if you invested $1,000 astatine the clip of our recommendation, you’d person $1,072,908!*